We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Catalyst Biosciences Inc | NASDAQ:CBIO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.5113 | 0.53 | 0.5796 | 0 | 01:00:00 |
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
||
|
|
|
Exhibit Number
|
Exhibit Title or Description
|
|
Press Release, dated November 6, 2023
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
GYRE THERAPEUTICS, INC.
|
||
Date: November 6, 2023
|
By:
|
/s/ Charles C. Wu, Ph.D.
|
Name:
|
Charles C. Wu, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Company Name:
|
GNI Group Ltd.
|
|
Representative:
|
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
|
|
(Security Code: 2160, TSE Growth)
|
||
Contact Person:
|
Chief Financial Officer
Toshiya Kitagawa
|
|
(TEL. 03-6214-3600)
|
Revenue
|
Operating profit
|
Profit before tax
|
Profit for the year
|
Profit attributable to owners of the parent
|
Basic earnings per share
|
|
(JPY Million)
|
(JPY Million)
|
(JPY Million)
|
(JPY Million)
|
(JPY Million)
|
(JPY)
|
|
Previous Forecast (A)
|
25,273
|
5,991
|
4,143
|
2,174
|
1,703
|
35.86
|
Revised Forecast (B)
|
26,267
|
7,280
|
6,430
|
4,351
|
2,005
|
42.20
|
Difference (B-A)
|
994
|
1,289
|
2,287
|
2,177
|
302
|
-
|
Difference in ratio (%)
|
3.9%
|
21.5%
|
55.2%
|
100.1%
|
17.7%
|
-
|
(Reference) 2022 Actual
|
17,418
|
1,377
|
767
|
(868)
|
388
|
8.19
|
Document and Entity Information |
Nov. 06, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 06, 2023 |
Entity File Number | 000-51173 |
Entity Registrant Name | Gyre Therapeutics, Inc. |
Entity Central Index Key | 0001124105 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2020050 |
Entity Address, Address Line One | 12730 High Bluff Drive |
Entity Address, Address Line Two | Suite 250 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | 650 |
Local Phone Number | 266-8674 |
Title of 12(b) Security | Common Stock |
Trading Symbol | GYRE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
1 Year Catalyst Biosciences Chart |
1 Month Catalyst Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions